Flavocure Biotech

Flavocure Biotech Inc. aims to become a leader in transforming natural products into new therapies for patients. The company has discovered several promising new drug candidates. Collaborating with some of the most prestigious research institutions worldwide, Flavocure is advancing these candidates through clinical studies. Preliminary data suggest that Flavocure’s drug candidates are active against known driver mutations and cancer-related targets. Caflanone, Flavocure's lead candidate, received FDA Orphan Drug Designation in 2019 for the treatment of pancreatic cancer.